News Room

Latest Announcements

Clinical Trials

Prana Provides Clinical Trials Update

Prana Biotechnology today reported on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer’s disease. Across the two trials approximately 37% have been dosed to 6 months or longer, twice the duration of the previous Phase II Alzheimer’s trial . 1,2 PBT2 has been well tolerated and both trials are on schedule with very pleasing retention rates and compliance. Each Independent Data Safety Monitoring Board for the two trials met at the end of March and recommended that each trial continue as planned without any protocol changes.

Investor Announcement

Prana Details Data Showing that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment.

1 6 7 8 9 10 11